Litcius/Paper detail

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

M-J. Ahn, Aaron Lisberg, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Jacob Sands, Richard D. Hall, Yong Zhang, H. Zebger-Gong, Deise Uema, Isamu Okamoto

2023Annals of Oncology55 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDocetaxelInternal medicineOncologynon-small cell lung cancer (NSCLC)NauseaVinorelbinePhases of clinical researchLung cancerChemotherapyGastroenterologyCisplatinA549 cellLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research
LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 | Litcius